Literature DB >> 1851379

Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization.

N Nakoa1, K Kamino, K Miura, T Hayashi, M Ohnishi, Y Takayasu, T Miura, E Okamoto.   

Abstract

The usefulness of transcatheter arterial chemoembolization (TACE) of the hepatic artery was retrospectively evaluated in 66 patients who underwent the procedure for treatment of hepatocellular carcinoma that recurred after partial hepatectomy. The materials infused were Gelfoam sponge or Gelfoam sponge plus Lipiodol and an anticancer agent. A control group of 15 patients with recurrent tumor received oral anticancer agents alone. The cumulative survival rate for the TACE group was 88% for the first year, 57% for 2 years, 42% for 3 years, and 27% for 5 years, whereas that of the control group was 80% for the first year, 27% for 2 years, and 18% for 3 years. Thus, the prognosis of the TACE group was significantly better (p less than or equal to .01, log-rank test) than that of the control group. The survival rate was inversely correlated with the ratio of the volume of the recurrent tumor to the volume of the whole residual liver. These results suggest that TACE is more effective than oral chemotherapy for treatment of hepatocellular carcinoma that recurs after partial hepatectomy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851379     DOI: 10.2214/ajr.156.6.1851379

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Regional Therapy of Hepatic Malignancies.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

2.  Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma.

Authors:  Masami Minagawa; Masatoshi Makuuchi; Tadatoshi Takayama; Norihiro Kokudo
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

3.  Clinical management of recurrent hepatocellular carcinoma.

Authors:  P H Lee; W J Lin; Y M Tsang; R H Hu; J C Sheu; M Y Lai; H C Hsu; W May; C S Lee
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

4.  Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.

Authors:  Bo-Ching Lee; Kao-Lang Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

5.  Appropriate treatment strategy for intrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.

Authors:  Fumitoshi Hirokawa; Michihiro Hayashi; Yoshiharu Miyamoto; Mitsuhiro Asakuma; Tetsunosuke Shimizu; Koji Komeda; Yoshihiro Inoue; Nobuhiko Tanigawa
Journal:  J Gastrointest Surg       Date:  2011-05-10       Impact factor: 3.452

Review 6.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 7.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

8.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; J Wong
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

9.  Prognostic impact of treatment modalities on patients with single nodular recurrence of hepatocellular carcinoma.

Authors:  Masaki Ueno; Kazuhisa Uchiyama; Satoru Ozawa; Takayuki Nakase; Naoki Togo; Shinya Hayami; Hiroki Yamaue
Journal:  Surg Today       Date:  2009-07-29       Impact factor: 2.549

10.  Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection.

Authors:  Hadrien Tranchart; Mircea Chirica; Ailton Sepulveda; Pierre-Philippe Massault; Filomena Conti; Olivier Scatton; Olivier Soubrane
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.